Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

853 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Jabbour E, et al. Among authors: ravandi f. Cancer. 2017 Jan 1;123(2):294-302. doi: 10.1002/cncr.30264. Epub 2016 Sep 7. Cancer. 2017. PMID: 27602508 Free PMC article.
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Ravandi F, et al. Bone Marrow Transplant. 2001 Jun;27(12):1221-5. doi: 10.1038/sj.bmt.1703028. Bone Marrow Transplant. 2001. PMID: 11548839 Clinical Trial.
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. de Lima M, et al. Among authors: ravandi f. Cancer. 2003 Mar 1;97(5):1242-7. doi: 10.1002/cncr.11184. Cancer. 2003. PMID: 12599231 Free article. Clinical Trial.
Investigational agents in myeloid disorders.
Ravandi F, Cortes J. Ravandi F, et al. Adv Pharmacol. 2004;51:59-97. doi: 10.1016/S1054-3589(04)51003-7. Adv Pharmacol. 2004. PMID: 15464905 Review. No abstract available.
Alemtuzumab.
Ravandi F, O'Brien S. Ravandi F, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):39-51. doi: 10.1586/14737140.5.1.39. Expert Rev Anticancer Ther. 2005. PMID: 15757437 Review.
853 results